SPDL1 and renal cell carcinoma: Most studies have found that high pretreatment sPD-L1 levels are associated with decreased survival in patients with advanced solid tumors (e.g., lung cancer, gastric cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, pancreatic cancer, and soft tissue sarcoma)31,33,35–43.